GlassScriptPhysician profile
Merlyn Varona
NPI 1295349173
$8,822.09
in general payments reported to CMS, 2019-2025
47 companies · $2,670 in 2025
The $2,670 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $1,101 · 2023: $1,790 · 2024: $2,674 · 2025: $2,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,122 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,121.83 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,609.24 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,052.08 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $590.72 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $581.77 | 2022-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $408.78 | 2022-2025 | |
| Janssen Biotech, INC. | $398.41 | 2021-2023 | Erleada |
| Theratechnologies INC. | $367.55 | 2024-2025 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $364.44 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $291.51 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $231.17 | 2023-2025 | |
| Daiichi Sankyo INC. | $143.23 | 2021-2023 | Enhertu |
| Emd Serono, INC. | $137.22 | 2024-2025 | |
| Novo Nordisk INC | $126.65 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Morphosys, US INC. | $122.73 | 2022-2023 | Monjuvi |
| Eisai INC. | $115.64 | 2021-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merlyn Varona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.